Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients withworsening chronic heart failure and reduced ejection fraction the socrates-reduced randomized trial

JAMA - Journal of the American Medical Association

Volumn 314, Issue 21, 2015, Pages 2251-2262

  Gheorghiade, Mihai ^a   Greene, Stephen J ^b   Butler, Javed ^c   Filippatos, Gerasimos ^d   Lam, Carolyn S P ^e   Maggioni, Aldo P ^f   Ponikowski, Piotr ^g   Shah, Sanjiv J ^a   Solomon, Scott D ^h   Kraigher Krainer, Elisabeth ⁱ   Samano, Eliana T ^j   Muller, Katharina ^k   Roessig, Lothar ^l   Pieske, Burkert ⁱ  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^e DEPARTMENT OF CARDIOLOGY   (Singapore)

^f ANMCO RESEARCH CENTER   (Italy)

^g WROCLAW MEDICAL UNIVERSITY   (Poland)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j Bayer   (Brazil)

^k BAYER PHARMA AG   (Germany)

^l DEUTSCHES HERZZENTRUM BERLIN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; PLACEBO; VERICIGUAT; BRAIN NATRIURETIC PEPTIDE; FUSED HETEROCYCLIC RINGS; GUANYLATE CYCLASE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PYRIMIDINE DERIVATIVE;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAINTNESS; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; CHRONIC DISEASE; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; HOSPITALIZATION; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHRONIC DISEASE; FEMALE; GUANYLATE CYCLASE; HEART FAILURE; HETEROCYCLIC COMPOUNDS, 2-RING; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PYRIMIDINES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84949489402     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.15734     Document Type: Article

References (23)

1. Blecker S, Paul M, Taksler G, Ogedegbe G, Katz S. Heart failure-associated hospitalizations in the United States. J AmColl Cardiol. 2013;61(12):1259-1267.
2. Gheorghiade M, Pang PS. Acute heart failure syndromes. J AmColl Cardiol. 2009;53(7):557-573.
3. Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acutemyocardial infarction, or pneumonia. JAMA. 2013;309(4):355-363.
4. Krumholz HM, Normand SL,Wang Y. Trends in hospitalizations and outcomes for acute cardiovascular disease and stroke, 1999- 2011. Circulation. 2014;130(12):966-975.
5. Skali H, Dwyer EM, Goldstein R, et al. Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT. Eur J Heart Fail. 2014;16 (5):56 0-565.
6. Gheorghiade M, Marti CN, Sabbah HN, et al; Academic Research Team in Heart Failure (ART-HF). Soluble guanylate cyclase: A potential therapeutic target for heart failure. Heart Fail Rev. 2013;18(2 ): 123-134.
7. Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther. 2009;122(3):216-238.
8. Greene SJ, Gheorghiade M, Borlaug BA, et al. The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J AmHeart Assoc. 2013;2(6):e000536.
9. Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. J AmColl Cardiol. 2012;60(16):1455-1469.
10. McKie PM, Schirger JA, Costello-Boerrigter LC, et al. Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. J AmColl Cardiol. 2011;58(20):2095-2103.
11. Pieske B, Butler J, Filippatos G, et al; SOCRATES Investigators and Coordinators. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail. 2014;16(9):1026-1038.
12. Bonderman D, Ghio S, Felix SB, et al; Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Rio ciguat Trial (LEPHT) Study Group. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: A phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013;128( 5):502-511.
13. Taylor AL, Ziesche S, Yancy C, et al; African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351 (20):2049-2057.
14. McMurray JJ, Packer M, Desai AS, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004.
15. Gupta D, Georgiopoulou VV, Kalogeropoulos AP, et al. Nitrate therapy for heart failure: Benefits and strategies to overcome tolerance. JACC Hear t Fail. 2013;1(3):183-191.
16. Sharkovska Y, Kalk P, Lawrenz B, et al. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens. 2010;28(8):1666-1675.
17. Benz K, Orth SR, Simonaviciene A, et al. Blood pressure-independent effect of long-term treatment with the soluble heme-indep endent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage. Kidney Blood Press Res. 2007;30(4):224-233.
18. Masuyama H, Tsuruda T, Kato J, et al. Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension. 2006;48(5):972-978.
19. Vaduganathan M, Butler J, Pitt B, Gheorghiade M. Contemporary drug development in heart failure: Call for hemodynamically neutral therapies. Circ Heart Fail. 2015;8(4):826-831.
20. Patel PA, Heizer G, O'Connor CM, et al. Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: Findings from ASCEND-HF. Circ Heart Fail. 2014;7(6):918-925.
21. Ambrosy AP Vaduganathan M Mentz RJ et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: Insights from the Efficacy of Vasop ressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. Am Heart J. 2013.165. 2. 216-225.
22. Gheorghiade M, Bö hm M, Greene SJ, et al; ASTRONAUT Investigator s and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: The ASTRONAUT randomized trial. JAMA. 2013;309(11):1125-1135.
23. Greene SJ,Maggioni AP, Fonarow GC, et al; ASTRONAUT Investigators and Coordinators. Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: Findings from the ASTRONAUT trial. Eur J Heart Fail. 2015;17(1):98-108.